New intravital optical imaging technologies have revolutionized our understanding of mammalian biology and continue to evolve rapidly. However, there are only a limited number of imaging probes available to date. In this study, we investigated in mouse models of glioblastoma whether a fluorescent small molecule inhibitor of the DNA repair enzyme PARP1, PARPi-FL, can be used as an imaging agent to detect glioblastomas in vivo. We demonstrated that PARPi-FL has appropriate biophysical properties, low toxicity at concentrations used for imaging, high stability in vivo, and accumulates selectively in glioblastomas due to high PARP1 expression. Importantly, subcutaneous and orthotopic glioblastoma xenografts were imaged with high contrast clearly defining tumor tissue from normal surrounding tissue. This research represents a step toward exploring and developing PARPi-FL as an optical intraoperative imaging agent for PARP1 in the clinic.
The DNA repair enzyme PARP1 is over-expressed in glioblastoma, with overall low expression in healthy brain tissue. Paired with the availability of specific molecularly targeted small molecules for this biomarker, PARP1 is a near-ideal target for novel radiotherapeutics. A successful PARP1-targeted radiotherapeutic would induce DNA damage and apoptosis in cancer cells, while sparing healthy brain tissue. We synthesized a 131I-labeled poly(ADP-ribose) polymerase 1 (PARP1) therapeutic and investigated its pharmacology using in vitro and in vivo methodologies. A subcutaneous mouse model was used to quantify retention times and therapeutic efficacy. A potential clinical scenario, intratumoral convection-enhanced delivery (CED), was mimicked using an orthotopic glioblastoma model combined with an implanted osmotic pump system to study local administration of [131I]PARPi. [131I]PARPi is a 1(2H)-phthalazinone, similar in structure to the FDA-approved PARP inhibitor Olaparib (Lynparza, Astra-Zeneca). In vitro studies have shown that [131I]PARPi and Olaparib share similar pharmacologic profiles. [131I]PARPi delivers 134.1 cGy/MBq intratumoral injected activity; doses to non-target tissues, including liver and kidney, were significantly lower. Radiation damage and cell death could be shown by p53 activation via bioluminescence imaging in U87 MG cells transfected with a p53-bioluminescent reporter in treated tumors. Treated mice had significantly longer survival than mice receiving only vehicle (29 vs. 22 days, P < 0.005) in a subcutaneous model. CED demonstrated efficient retention of [131I]PARPi in orthotopic brain tumors, while quickly clearing from healthy brain tissue. We validated the novel PARP1-targeted radiotherapeutic [131I]PARPi, studying its performance in mouse models. Our results demonstrate [131I]PARPi’s high potential as a therapeutic, and highlight PARP's relevance as a target for radionuclide therapy. Radiation plays an integral role in brain tumor therapy, and radiolabeled PARP therapeutics could ultimately lead to improvements in the standard of care.
Over the last decade, exosomes from diverse biological sources have been proposed as new natural platforms in drug delivery. Translation of these nanometric tools to clinical practice requires deep knowledge of their pharmacokinetic properties and biodistribution. The pharmacokinetic properties of exosomes are sometimes evaluated using biochemical and histological techniques that are considerably invasive. As an alternative, we present radiochemical labeling of milk-derived exosomes based on reduced 99mTc (IV) without modifying biological and physicochemical properties. This approach enables longitudinal tracking of natural exosomes by non-invasive single photon emission computed tomography (SPECT) imaging and the evaluation of their pharmacokinetic properties according to the route of administration.
11 April 2011 in Microscopy Research and Technique